# Carfilzomib (Kyprolis)

Source: https://ourhealthnetwork.com/drugs/carfilzomib
Data: FDA Orange Book and OpenFDA, refreshed periodically

## What is Carfilzomib?

Carfilzomib (brand name: Kyprolis) is a proteasome inhibitor. It is prescribed to treat multiple myeloma.

## Brand names

Kyprolis

## Indications

Carfilzomib is primarily prescribed for the treatment of multiple myeloma.

## Conditions treated

- [Multiple Myeloma](https://ourhealthnetwork.com/conditions/multiple-myeloma)

## Mechanism of action

Carfilzomib is a tetrapeptide epoxyketone proteasome inhibitor that irreversibly binds to the N-terminal threonine-containing active sites of the 20S proteasome, the proteolytic core particle within the 26S proteasome. Carfilzomib had antiproliferative and proapoptotic activities in vitro in solid and hematologic tumor cells.

## Drug classification

- Established Pharmacologic Class: Proteasome Inhibitor [EPC]
- Mechanism of Action class: Proteasome Inhibitors [MoA]
- Route of administration: INTRAVENOUS

## Common side effects

There were 274 (70%), Decreased lymphocytes 15 (63), Fatigue 14 (58), 14 (58), Pyrexia 14 (58), bortezomib and dexamethasone Decreased lymphocytes 249 (54), Thrombocytopenia 13 (54), 13 (54)

## Sources and disclaimers

- FDA Orange Book and OpenFDA dataset
- This information is for educational purposes only and does not constitute medical advice. Always consult a healthcare professional before starting, stopping, or changing any medication.

## Related

- [All drugs](https://ourhealthnetwork.com/drugs)
- [Find specialists who prescribe this drug](https://ourhealthnetwork.com/find-doctors)
- [Methodology](https://ourhealthnetwork.com/methodology)